Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Holle, Julia U ^a   Moosig, Frank ^a   Dalhoff, Klaus ^a   Gross, Wolfgang L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GEMCITABINE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; PREDNISONE; PROPYLTHIOURACIL; RETINOIC ACID; RITUXIMAB; SILICON DIOXIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; AORTA ARCH SYNDROME; ASTHMA; BEHCET DISEASE; BRONCHOSCOPY; CAPILLARITIS; CD4+ T LYMPHOCYTE; CHURG STRAUSS SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CRYOGLOBULINEMIA; CRYOGLOBULINEMIC VASCULITIS; DISEASE COURSE; DRUG MEGADOSE; FIBEROPTIC BRONCHOSCOPY; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; GRANULOMATOUS INFLAMMATION; GRANULOMATOUS VASCULITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOLOGY; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION TEST; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; MICROSCOPIC POLYANGIITIS; OCCUPATIONAL EXPOSURE; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; POLYARTERITIS NODOSA; PROTEIN EXPRESSION; PULMONARY VASCULITIS; REVIEW; RHEUMATIC DISEASE; RHINITIS; WEGENER GRANULOMATOSIS; LUNG DISEASE; PATHOPHYSIOLOGY; VASCULITIS;

HUMANS; LUNG DISEASES; RHEUMATIC DISEASES; VASCULITIS;

EID: 80052245553     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3307     Document Type: Review

References (93)

1. Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990, 33:1135-1136.
2. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192. 10.1002/art.1780370206, 8129773.
3. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
4. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nölle B, Heller M, Gross WL. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000, 43:1021-1032. 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J, 10817555.
5. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990, 87:4115-4119. 10.1073/pnas.87.11.4115, 54058, 2161532.
6. Calderwood JW, Williams JM, Morgan MD, Nash GB, Savage CO. ANCA induces beta2 integrin and CXC chemokine-dependent neutrophilendothelial cell interactions that mimic those of highly cytokine-activated endothelium. J Leukoc Biol 2005, 77:33-43.
7. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC. Antineutrophil cytoplasmatic antibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955-963. 151154, 12370273.
8. Fienberg R. Pathergic granulomatosis. Am J Med 1955, 19:829-831. 10.1016/0002-9343(55)90150-9, 13275478.
9. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL. Clin Exp Immunol 1995, 101(suppl 1):29-34. 1553550, 7606858.
10. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott DG, Witter J, Yazici H, Luqmani RA. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibodyassociated vasculitis. Ann Rheum Dis 2007, 66:605-617. 10.1136/ard.2006.062711, 2703775, 17170053.
11. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, . European Vasculitis Study Group EULAR recommendations for the management of primary small vessel vasculitis. Ann Rheum Dis 2009, 68:310-317. 10.1136/ard.2008.088096, 18413444, European Vasculitis Study Group.
12. Anderson G, Coles ET, Crane M, Douglas AC, Gibbs AR, Geddes DM, Peel ET, Wood JB. Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. QJM 1992, 83:427-438.
13. Holle JU, Gross WL, Holl-Ulrich K, Ambrosch P, Noelle B, Both M, Csernok E, Moosig F, Schinke S, Reinhold-Keller E. Prospective long-term follow-up of patients with localized Wegener's granulomatosis: does it occur as persisten disease stage?. Ann Rheum Dis 2010, 69:1934-1939. 10.1136/ard.2010.130203, 20511614.
14. Reuter M, Schnabel A, Wesner F, Tetzlaff K, Risheng Y, Gross WL, Heller M. Pulmonary Wegnener's granulomatosis: correlation between high resolution CT findings and clinical scoring of disease activity. Chest 1998, 114:500-506. 10.1378/chest.114.2.500, 9726737.
15. Komócsi A, Reuter M, Heller M, Muraközi H, Gross WL, Schnabel A. Active disease and residual damage in treated Wegener's granulomatosis: an observational study using pulmonary high-resolution computed tomography. Eur Radiol 2003, 13:36-42.
16. Haworth SJ, Savage CO, Carr D, Hughes JM, Rees AJ. Pulmonary haemorrhage complicating Wegener's granulomatosis and microscopic polyarteriitis. BMJ 1985, 290:1775-1778. 10.1136/bmj.290.6484.1775, 1415961, 3924249.
17. Thickett DR, Richter AG, Nathani N, Perkins GD, Harper L. Pulmonary manifestations of anti-neutrophil cytoplasmic antibody (ANCA-) positive vasculitis. Rheumatology 2006, 45:261-268.
18. Schnabel A, Reuter M, Gloeckner K, Müller-Quernheim J, Gross WL. Bronchoalveolar lavage cell profiles in Wegener's granulomatosis. Respir Med 1999, 93:498-506. 10.1016/S0954-6111(99)90093-8, 10464837.
19. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, Amouroux J, Casassus P, Jarrousse B. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999, 42:421-430. 10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6, 10088763.
20. Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteriitis nodosa, microscopic polyangiitis, Wegener's granulomatosis and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004, 51:92-99. 10.1002/art.20077, 14872461.
21. Savage CO, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteriitis: presentation, pathology and prognosis. QJMed 1985, 56:467-483.
22. Lhote F, Cohen P, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Lupus 1998, 7:238-258. 10.1191/096120398678920055, 9643314.
23. Hervier B, Pagnoux C, Agard C, Haroche J, Amoura Z, Guillevin L, Hamidou MA, . French Vasculitis Study Group Pulmonary firbosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis 2009, 68:404-407. 10.1136/ard.2008.096131, 18957485, French Vasculitis Study Group.
24. Becker-Merok A, Nossent JC, Ritland N. Fibrosing alveolitis predating mocroscopic polyangiitis. Scand J Rheumatol 1999, 28:254-256. 10.1080/03009749950155643, 10503564.
25. Birnbaum J, Danoff S, Askin FB, Stone JH. Microscopic polyangiitis presenting as a "pulmonary-muscle" syndrome: is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis?. Arthritis Rheum 2007, 56:2065-2071. 10.1002/art.22633, 17530647.
26. Tzelepis GE, Kokosi M, Tzioufas A, Toya SP, Boki KA, Zormpala A, Moutsopoulos HM. Prevalence and outcome of pulmonary fibrosis microscopic polyangiitis. Eur Respir J 2010, 36:116-121. 10.1183/09031936.00110109, 19926741.
27. Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, Grasselli C, Pavone L, Gregorini G, Monti S, Frassi M, Vecchio F, Corace C, Venegoni E, Buzio C. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005, 52:2926-2935. 10.1002/art.21250, 16142760.
28. Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME, Rosenwasser LJ, Roufosse F, Gleich GJ, Klion AD. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126:45-49. 10.1016/j.jaci.2010.03.042, 20639008.
29. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984, 63:65-81.
30. Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007, 19:25-32. 10.1097/BOR.0b013e3280119854, 17143092.
31. Dennert RM, van Paassen P, Schalla S, Kuznetsova T, Alzand BS, Staessen JA, Velthuis S, Crijns HJ, Tervaert JW, Heymans S. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum 2010, 62:627-634.
32. Wieczorek S, Hellmich B, Arning L, Moosig F, Lamprecht P, Gross WL, Epplen JT. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis. Arthritis Rheum 2008, 58:1839-1848. 10.1002/art.23496, 18512809.
33. Churg J, Strauss L. Allergic angiitis and periarteritis nodosa. Am J Pathol 1951, 27:277-301. 1937314, 14819261.
34. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, Thibult N, Casassus P. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996, 75:17-28. 10.1097/00005792-199601000-00003, 8569467.
35. Ribi C, Cohen P, Pagnoux C, Mahr A, Arène JP, Lauque D, Puéchal X, Letellier P, Delaval P, Cordier JF, Guillevin L, . French Vasculitis Study Group Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008, 58:586-594. 10.1002/art.23198, 18240234, French Vasculitis Study Group.
36. Keogh KA, Specks U. Churg-Strauss Syndrome. Clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003, 115:284-290. 10.1016/S0002-9343(03)00359-0, 12967693.
37. Cottin V, Kouatra C, Dubost R. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome. Allergy 2009, 64:589-595. 10.1111/j.1398-9995.2008.01854.x, 19154547.
38. Bibby S, Healy B, Steele R, Kumareswaran K, Nelson H, Beasley R. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax 2010, 65:132-138.
39. Schnabel A, Csernok E, Braun J, Gross WL. Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax 1999, 54:771-778. 10.1136/thx.54.9.771, 1745565, 10456969.
40. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, Savage C, Adu D. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994, 87:671-681.
41. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997, 40:371-380. 10.1002/art.1780400222, 9041949.
42. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:2461-2469. 10.1002/art.21142, 16052573.
43. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, . EUVAS (European Vasculitis Study Group) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009, 150:670-680. EUVAS (European Vasculitis Study Group).
44. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, . RAVE-ITN Research Group Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232. 10.1056/NEJMoa0909905, 20647199, RAVE-ITN Research Group.
45. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, . European Vasculitis Study Group Rituximab versus cyclophopshamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220. 10.1056/NEJMoa0909169, 20647198, European Vasculitis Study Group.
46. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD, . European Vasculitis Study Group Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18:2180-2188. 10.1681/ASN.2007010090, 17582159, European Vasculitis Study Group.
47. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C, . European Vasculitis Study Group A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:36-44. 10.1056/NEJMoa020286, 12840090, European Vasculitis Study Group.
48. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, Kyndt X, Lifermann F, Papo T, Lambert M, Le Noach J, Khellaf M, Merrien D, Puéchal X, Vinzio S, Cohen P, Mouthon L, Cordier JF, Guillevin L, . French Vasculitis Study Group Azathioprine of methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008, 359:2790-2803. 10.1056/NEJMoa0802311, 19109574, French Vasculitis Study Group.
49. Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, Gross WL, Reinhold-Keller E, . German Network of Rheumatic Diseases Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology 2007, 46:1087-1091. 10.1093/rheumatology/kem029, 17519271, German Network of Rheumatic Diseases.
50. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprimsulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996, 335:16-20. 10.1056/NEJM199607043350103, 8637536.
51. Reinhold-Keller E, De Groot K, Rudert H, Nölle B, Heller M, Gross WL. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996, 89:15-23.
52. Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. Rheumatology 2001, 40:492-498. 10.1093/rheumatology/40.5.492, 11371656.
53. Bligny D, Mahr A, Toumelin PL, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 2004, 51:83-91. 10.1002/art.20082, 14872460.
54. Matteson EL, Gold KN, Bloch DA. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's granulomatosis classification cohort. Am J Med 1996, 101:129-134. 10.1016/S0002-9343(96)80066-0, 8757351.
55. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM 2005, 98:97-111. 10.1093/qjmed/hci015, 15655098.
56. Aasarød K, Iversen BM, Hammerstrøm J, Bostad L, Vatten L, Jørstad S. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000, 15:611-618. 10.1093/ndt/15.5.611, 10809800.
57. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002, 100:82-85. 10.1002/ijc.10444, 12115591.
58. Eriksson P, Jacobsson L, Lindell A, Nilsson JA, Skogh T. Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J Intern Med 2009, 265:496-506. 10.1111/j.1365-2796.2008.02060.x, 19141094.
59. Holle JU, Gross WL, Latza U, Nölle B, Ambrosch P, Heller M, Fertmann R, Reinhold-Keller E. Improved outcome of 445 Wegener's granulomatosis patients in a German vasculitis center over four decades. Arthritis Rheum 2010, 63:257-266.
60. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, Jayne D, Harper L, . European Vasculitis Study (EUVAS) Group Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010, 69:1036-1043. 10.1136/ard.2009.109389, 19574233, European Vasculitis Study (EUVAS) Group.
61. Metzler C, Hellmich B, Gause A, Gross WL, de Groot K. Churg-Strauss-Syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance therapy. Clin Exp Rheumatol 2004, 22:S52-61.
62. Solans R, Bosch JA, Pérez-Bocanegra C, Selva A, Huguet P, Alijotas J, Orriols R, Armadans L, Vilardell M. Churg-Strauss syndrome: outcome and longterm follow-up of 32 patients. Rheumatology 2001, 40:763-771. 10.1093/rheumatology/40.7.763, 11477281.
63. Tatsis E, Schnabel A, Gross WL. Interferon-α treatment of four patients with the Churg-Strauss-Syndrome. Ann Int Med 1998, 129:370-374.
64. Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferonalpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2008, 26:S35-40.
65. Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D, Pusey CD, Salama AD. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008, 47:1104-1105.
66. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002, 206:496-501. 10.1078/0171-2985-00197, 12607724.
67. Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010, 125:1336-1343. 10.1016/j.jaci.2010.03.028, 20513524.
68. Moosig F, Butherus K, Hellmich B, Gross WL. Mepolizumab, a humanized IL-5 antibody, has steroid-sparing potential in Churg-Strauss-Syndrome. Arthritis Rheum 2010, 62:S925.
69. Chan AL, Louie S, Leslie KO, Juarez MM, Albertson TE. Cutting edge issues in Goodpasture's disease. Clin Rev Allergy Immunol 2011,
70. Saulsbury T. Henoch-Schonlein purpura. Curr Opin Rheumatol 2010, 22:598-602. 10.1097/BOR.0b013e32833af608, 20473173.
71. Ferri C, Mascia MT. Cryoglobulinemic vasculitis. Curr Opin Rheumatol 2006, 18:54-63.
72. Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, Bienvenu B, Mouthon L, Guillevin L, . French Vasculitis Study Group Clinical features and outcomes in 348 patients with polyarteritis nodosa. Arhtritis Rheum 2010, 62:616-626. French Vasculitis Study Group.
73. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, . European Vasculitis Study Group EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009, 68:310-317. 10.1136/ard.2008.088096, 18413444, European Vasculitis Study Group.
74. Mason C. Takayasu arteritis-advances in diagnosis and treatment. Nat Rev Rheumatol 2010, 6:406-415. 10.1038/nrrheum.2010.82, 20596053.
75. Ceylan N, Bayraktaroglu S, Erturk SM, Savas R, Alper H. Pulmonary and vascular manifestations of Behcet disease: Imaging findings. AJR Am J Roentgenol 2010, 194:W158-W164. 10.2214/AJR.09.2763, 20093567.
76. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kötter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stübiger N, Yurdakul S, Yazici H, . EULAR Expert Committee EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008, 67:1656-1662. 10.1136/ard.2007.080432, 18245110, EULAR Expert Committee.
77. Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis - incidence and risk factors. Rheumatology 2008, 47:530-534.
78. Csernok E, Lamprecht P, Gross WL. Clinical and immunological features of drug-indeuced and infection-induced proteinase 3-antirneutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. Curr Opin Rheumatol 2010, 22:43-48. 10.1097/BOR.0b013e3283323538, 19770659.
79. Hogan SL, Cooper GS, Savitz DA, Nylander-French LA, Parks CG, Chin H, Jennette CE, Lionaki S, Jennette JC, Falk RJ. Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based case-control study. Clin J AM Soc Nephrol 2007, 2:290-299. 10.2215/CJN.03501006, 17699427.
80. Knight A, Sandin S, Askling J. Occupational risk factors for Wegener's granulomatosis: a case-control study. Ann Rheum Dis 2010, 69:737-740. 10.1136/ard.2009.107953, 19364729.
81. Moosig F, Holle JU, Gross WL. Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?. Arthritis Res Ther 2009, 11:253. 10.1186/ar2826, 2787252, 19886977.
82. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, Lesavre P, Jacquot C, Bindi P, Bielefeld P, Desson JF, Détrée F, Dubois A, Hachulla E, Hoen B, Jacomy D, Seigneuric C, Lauque D, Stern M, Longy-Boursier M. A prospective multicenter randomized trial comparing steroids and pulse cyclophosphamide versussteroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997, 40:2187-2198. 10.1002/art.1780401213, 9416856.
83. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonphritis and systemic vasculitis. Ann Intern Med 1990, 113:656-663.
84. Charlier C, Henegar C, Launay O, Pagnoux C, Berezné A, Bienvenu B, Cohen P, Mouthon L, Guillevin L. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 2009, 68:658-663. 10.1136/ard.2008.088302, 18504289.
85. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, Savage CO, Jayne DR. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2156-2168. 10.1002/art.24637, 19565480.
86. Flossmann O, Baslund B, Bruchfeld A, Tervaert JW, Hall C, Heinzel P, Hellmich B, Luqmani RA, Nemoto K, Tesar V, Jayne DR. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2009, 68:1125-1130. 10.1136/ard.2008.092429, 18713783.
87. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suárez LF, van der Woude FJ, . European Vasculitis Study Group Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004, 65:1440-1448. 10.1111/j.1523-1755.2004.00534.x, 15086487, European Vasculitis Study Group.
88. Ognibene FP, Shelhamer JH, Hoffman GS, Kerr GS, Reda D, Fauci AS, Leavitt RY. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995, 151:795-799.
89. Godeau B, Mainardi JL, Roudot-Thoraval F, Hachulla E, Guillevin L, Huong Du LT, Jarrousse B, Remy P, Schaeffer A, Piette JC. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis 1995, 54:991-994. 10.1136/ard.54.12.991, 1010066, 8546533.
90. Swoden E, Carmicheal AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis 2004, 4:42-48. 10.1186/1471-2334-4-42, 526257, 15488151.
91. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Prof 1996, 71:5-13.
92. Bligny D, Mahr A, Toumelin PL, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener's granulomatosis: a survival based analysis based on 93 patients. Arthritis Rheum 2004, 51:83-91. 10.1002/art.20082, 14872460.
93. Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. Rheumatology 2001, 40:492-498. 10.1093/rheumatology/40.5.492, 11371656.